Announced details
Drug information provision for pharmaceutical companies, information provision to medical institutions, health insurance pharmacies and nursing-care facilities, inquiry and appropriate-use support, and recruitment support
Through Collabo Portal and other channels, the service has contact with more than 480,000 healthcare and nursing-care professionals. EPファーマライン supports more than 300 pharmaceutical and medical-device companies. Initial offerings have begun for multiple pharmaceutical companies.
EPファーマライン and SUZUKEN entered into a basic agreement on 14 May 2026. 株式会社コラボスクエア is a consolidated subsidiary of SUZUKEN. EPファーマライン and the SUZUKEN Group will jointly roll out the service.
SUZUKEN CO.,LTD. is headquartered in Nagoya, and its representative director is Asano Shigeru (浅野茂). 株式会社コラボスクエア is a consolidated subsidiary of SUZUKEN, headquartered in Chuo-ku, Tokyo, and its representative director is Andoi Tats (安藤井達). The names and profiles of the pharmaceutical companies have not been disclosed.
AI-MS is registered as a trademark by 株式会社コラボスクエア. The registration number, registration date and expiry date have not been disclosed.
EPファーマライン headquarters: Ikebukuro West Park Building, 3-27-12 Nishi-Ikebukuro, Toshima-ku, Tokyo. SUZUKEN headquarters: 8 Higashikatabata-cho, Higashi-ku, Nagoya. 株式会社コラボスクエア headquarters: Chuo-ku, Tokyo.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | CS Assist Line (drug information and inquiry support service), Collabo Portal (collaboration portal), Medical Care Station (MCS), AI-MS, Medical Contact Center |
| Counterparty | SUZUKEN CO.,LTD., 株式会社コラボスクエア, Pharmaceutical companies (multiple companies; names not disclosed) |
| Counterparty overview | SUZUKEN CO.,LTD. is headquartered in Nagoya, and its representative director is Asano Shigeru (浅野茂). 株式会社コラボスクエア is a consolidated subsidiary of SUZUKEN, headquartered in Chuo-ku, Tokyo, and its representative director is Andoi Tats (安藤井達). The names and profiles of the pharmaceutical companies have not been disclosed. |
| Relationship with the Company | EPファーマライン and SUZUKEN entered into a basic agreement on 14 May 2026. 株式会社コラボスクエア is a consolidated subsidiary of SUZUKEN. EPファーマライン and the SUZUKEN Group will jointly roll out the service. |
| Contract Date | 14 May 2026 (basic agreement) |
| Launch date | October 2026 (scheduled start of joint rollout and introductions). Initial offerings have already begun for multiple pharmaceutical companies. |
| Applicable area | Drug information provision for pharmaceutical companies, information provision to medical institutions, health insurance pharmacies and nursing-care facilities, inquiry and appropriate-use support, and recruitment support |
| Registration number and expiry date | AI-MS is registered as a trademark by 株式会社コラボスクエア. The registration number, registration date and expiry date have not been disclosed. |
| Location | EPファーマライン headquarters: Ikebukuro West Park Building, 3-27-12 Nishi-Ikebukuro, Toshima-ku, Tokyo. SUZUKEN headquarters: 8 Higashikatabata-cho, Higashi-ku, Nagoya. 株式会社コラボスクエア headquarters: Chuo-ku, Tokyo. |
| Usage history | Through Collabo Portal and other channels, the service has contact with more than 480,000 healthcare and nursing-care professionals. EPファーマライン supports more than 300 pharmaceutical and medical-device companies. Initial offerings have begun for multiple pharmaceutical companies. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To support more efficient information-provision activities by pharmaceutical companies, maintain a specialized support structure for inquiries and appropriate use, and provide healthcare and nursing-care professionals with information promptly and consistently.